Forte Medical case study within Imperial College Innovation paper

Commissioned by Lord Sainsbury and authored by Professor James Moore and Yunus Kutlu, Imperial College has published a report on innovation adoption in the UK and wh

at prevents successful adoption of impactful innovation. Forte Medical features as the only case study and outlines issues with silo systems, a disconnect between procurement and fincance all topped off with vested interests from labs and leadership.

The Peezy Midstream case study outlines how adoption of preventative devices and practice are resisted, leading to missed opportunities for improved patient health, prompt diagnoses, prevention and huge cost savings across the patient pathway.

Read all about it here. – see Page 29 and Appendix 2

Imperial Business School: a MedTech to Market Journey

Giovanna’s annual talk to the Imperial Business School took place last week; here we share the presentation Deck. Had she known in 2002 what she knows now, it would have taken a third of the time to create three specimen collection products and a springboard to global reach. She and Dr Vincent Forte are beyond proud of what they have achieved. 202210_ForteMedical_HealthTech_Commercialisation_Journey

US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

Comment: The Basic Diagnostic Failure That Affects 1 in 3 Women

Its time to reignite our NHS! Now our beloved health system has been blessed with new funding, we can furnish every hospital and GP practice with the latest digital technology and AI. We can burnish the reputations of our healthcare leaders because they have modernized patient care. 

It seems it is so much easier to spend new money, than it is to fix a failing system. Yet while this exciting digital revolution takes place, the Department of Health and NHS continue to fail 15m patients every year, whilst flushing £1.2bn of public funds down the loo. This is more than a shame; it’s a scandal.

There is one basic diagnostic process which is not as sexy as glittering new tech. It doesn’t excite our healthcare commentators. It will not invest our clinical leadership with shiny accolades that add kudos to reputation. It will not be covered by the media because it’s a waste product that no one really likes to talk about. Yet this waste product carries as much, if not more diagnostic clues to our health as its counterpart, blood. We need to talk about urine.

“If you don’t make the effort to collect the urine specimen properly, all the clever stuff you do later is pretty pointless. It’s a case of rubbish in, rubbish out,” says a Senior Microbiologist at Barts’ Heath NHS Trust. “The need for change is likely to be politically driven, rather than scientifically.”  The science is evident, the political will is not.

The lack of any protocol for urine collection is causing persistent, widespread and expensive diagnostic failure that starts in the GP surgery. For unreliable frontline diagnoses lead to critical conditions, hospital admissions, and expensive, complex treatment, not to mention the millions of patients who continue to suffer. This is not the fault of our hardworking and overstretched GPs and frontline nursing staff.  It is our healthcare leaders who persistently overlook the need to make urine analysis and treatment right-first-time.

Take urinary tract infection (UTI), a condition largely suffered by women. The last relevant data to come out of the NHS Unplanned Admissions Committee cites untreated UTI as the cause of 184,000 unplanned hospital admissions that cost the NHS £434m to treat (2013/14). This is hardly surprising when we know that 20-30% of initial antibiotic prescribing for UTI fails (Chronic Urinary Tract Infection Campaign CUTIC).

The majority of these annual 15m diagnostic failures will relate to women, who with UTI, suffer the most pain, most time off work and loss of income, whilst being prescribed the highest rate of broad-spectrum antibiotics, putting us firmly in the front line of antibiotic immunity. The need for a robust protocol around urine analysis has become critical. Data from CUTIC tells us that:

  • 1.4m women suffer from chronic bladder pain and urinary dysfunction
  • 1 in 3 women will have a UTI by the age of 24
  • 50% of dipstick tests don’t detect infection
  • 70% of infections risk recurrence within a year
  • 47% of Gram-negative blood infections have a urinary source and can lead to potentially fatal sepsis

NHS Improvement advises that 50% of the global rise in Antimicrobial Resistance (AMR) has a urinary cause; yet our health service still routinely relies on unreliable dipstick tests to indicate infection, leading to broad spectrum antibiotics remaining the first prescribing port of call; for the pregnant woman this is highly undesirable as it can extend life-long risk of antibiotic immunity to the unborn child.

Overuse of antibiotics is directly linked to the lack of a protocol for urine collection, transportation and analysis. National contamination rates are as high as 70% in some areas of the country, a postcode lottery situation that fails patients, microbiologists and the clinicians whose job it is to make people better. Non-invasive and cheap to collect, urine can help diagnose myriad conditions that cost the NHS billions of pounds. They include:

  • Kidney stones, infection and disease
  • Bladder cancer
  • Diabetes mellitus
  • Hypertension
  • Liver disease
  • Pre-eclampsia and other potentially serious pregnancy related conditions

Matt Hancock, Secretary of State for Health and Professor Tim Briggs, founding father of the Department of Health’s NHS Getting It Right First Time programme (GIRFT) both cite the need to eliminate variation in national diagnosis and treatment. We must challenge them to make the changes necessary to this most basic diagnostic process, to save lives, save money and create a solid foundation upon which the evolution of diagnostic medicine can flourish.

Right now, the best digital diagnostic technology in the world that relies on urine, won’t work. If the basics are right, the rest can follow. If they are not, then Mr Hancock and Professor Briggs … keep on flushing.

Urine specimen testing

Urine Is Liquid Gold When It Comes To Testing

Today’s Hippocratic Post features an overview on the importance of urine and the evidence supporting why our technology plays such a vital role in enabling right-first-time diagnosis and treatment.

 

Giovanna Forte What is Peezy Midstream

Maximising our MedTech Might

The benefits of working with the NIHR are clearly demonstrated through past posts and this is the latest to come out of Forte Medical NIHR partnership…

“CEO of Forte Medical, describes how the NIHR supported her company to generate clinical evidence for the Peezy™ Mid-Stream Urine device – an easier, cleaner and more reliable urine sample collection. Watch the full video here: https://lnkd.in/gY-6MMx

Or get in touch: supportmystudy@nihr.ac.uk

Infection prevention and control

IPC 2019 – We’re Exhibiting!

The future of preventative care, infection control, antimicrobial resistance and patient safety are routinely undermined by lazy attitudes towards urine collection, the most common diagnostic process.    Despite mounting evidence to support the need for a respected protocol, incumbent methods are failing modern medicine, patient health and the work of diligent clinicians.

Want to know more about our mission – visit us on stand 23 – and see first hand our world-class diagnostic specimen collection technology; Peezy Midstream reduces false-positive dipped urines by almost 70% and specimen contamination to just 2%. Current contamination is 23.5%, leading to 1 in 4 failed urine specimens – that’s over 14m annually or 56,000 every day. The unique Peezy Midstream delivers diagnostic integrity leading to targeted treatment; it helps address growing problems of infection control, unnecessary broad-spectrum antibiotic prescribing, AMR, and failed treatment of conditions that can become chronic.

Forte Medical Review

A Year In Review – 2018

  • New evidence showing a 70% reduction in false positive dipped specimens
  • Extended uptake by the NHS
  • Investment including a JV to create a Smart Peezy
  • Sheena Byrom joining our Advisory Panel
  • Being recognised in the Sunday Times 2018 Maserati 100 list that celebrate British entrepreneurship

These have been a few of our highlights for 2018 – to read more, please click here

Sheena Byrom Joins Our Advisory Panel

We are delighted to announce the appointment of consultant midwife and lifelong campaigner for positive childbirth, Sheena Byrom OBE to our Advisory Panel.

Sheena Byrom is a practising midwife of 40 years, having worked in the NHS for most of that time. One of the UK’s first consultant midwives, and as head of midwifery, she successfully helped to lead the development of three birth centres in East Lancashire. An international speaker, Sheena provides consultancy services to both NHS Trusts and to organisations globally; helping them to support normal, physiological childbirth. She is involved in several midwifery related charities, and is one of the project leads of the Midwifery Unit Network, which assists and promotes midwifery led units (birth centres) both online, and face-to-face. Sheena and her midwife daughter Anna Byrom are the proud new owners of The Practising Midwife, and an exciting online platform All4Materity.com – the go to place for maternity workers to learn, share and care.

Sheena’s midwifery memoirs, Catching Babies, is a Sunday Times bestseller, and her seminal book, The Roar Behind the Silence: why kindness, compassion and respect matter in maternity care jointly edited with Soo Downe, is being used as a resource to improve maternity care throughout the world.  Sheena and Soo are currently editing a second book, ‘Squaring the Circle: researching normal childbirth in a technological world’, will be published in 2019.

Sheena was awarded an OBE in 2011 for services to midwifery, and was made an Honorary Fellow of the Royal College of Midwives in 2015. In 2016 and 2018, Sheena received Honorary Doctorates from Bournemouth University and the University of Central Lancashire, and in 2017 she was made a Visiting Fellow at Bournemouth University. Her personal and midwifery related website is sheenabyrom.com.

Sheena is committed to the humanisation of childbirth, to maximising normal physiological birth processes, and for all women to experience a positive birth. The global onslaught of medical technology as a means to improve safety continues to influence childbearing women’s physiology and autonomy, and her work to reverse the trend is ongoing.

Commenting on her appointment, Giovanna Forte said: “With over 5 million urine samples provided every year by pregnant women and up to 1 in 4 of those being contaminated, it is incredibly important to us to have someone of Sheena’s expertise, knowledge and practical experience in the antenatal sector to help us.  We very much look forward to working with her to positively change attitudes towards urine specimen collection and further help improve right-first-time diagnosis and appropriate treatment for pregnant women as well as the well-being of mother and baby.”